| Id |
Subject |
Object |
Predicate |
Lexical cue |
| p2_i0 |
516-541 |
Pharmacological |
denotes |
AST-N020 y AST-N041 cards |
| p2_o4 |
1475-1534 |
Other |
denotes |
M. Armengol, J. Calvo, L. Martinez-Martinez (Santander, ES) |
| p1_all0 |
1501-1534 |
Intervention |
denotes |
Martinez-Martinez (Santander, ES) |
| p1_all1 |
1582-1616 |
Intervention |
denotes |
MicroScan WalkAway 96 system (W/A) |
| p1_all2 |
1738-1795 |
Population |
denotes |
organisms totally resistant or with low level resistance. |
| p1_all3 |
1818-2087 |
Population |
denotes |
278 clinical isolates (1 per patient) with different phenotypes of resistance to quinolones, including 108 E. coli, 43 P. mirabilis, 19 K. pneumoniae, 15 M. morganii, 11 C. freundii, 20 other enterobacteria, 47 P. aeruginosa, 11 A. baumannii and 4 other non fermenters. |
| p2_i1 |
1899-1909 |
Pharmacological |
denotes |
quinolones |
| p1_all4 |
2258-2529 |
Intervention |
denotes |
nalidixic acid (NAL) and to ciprofloxacin (CIP); Group 2 (26 E. coli and 34 non-E. coli): NAL-resistant (R), and with MIC of CIP ranging 0.5-2 mg/l; Group 3: (28 E. coli and 22 non-E. coli): NAL-R and CIP-R. W/A testing was done with Combo Urine 1S panels, containing NAL |
| p2_i2 |
2286-2305 |
Pharmacological |
denotes |
ciprofloxacin (CIP) |
| p1_all5 |
2572-2583 |
Intervention |
denotes |
norfloxacin |
| p2_i3 |
2572-2583 |
Pharmacological |
denotes |
norfloxacin |
| p1_all6 |
2606-2615 |
Intervention |
denotes |
ofloxacin |
| p2_i4 |
2606-2615 |
Pharmacological |
denotes |
ofloxacin |
| p1_all7 |
2798-2939 |
Outcome |
denotes |
clinical categories, number of minor, major (ME, false resistance) and very major errors (VME, false susceptibility), and essential agreement |
| p2_o8 |
2819-2864 |
Physical |
denotes |
number of minor, major (ME, false resistance) |
| p2_o8 |
2869-2914 |
Mental |
denotes |
very major errors (VME, false susceptibility) |
| p2_o8 |
2920-2939 |
Mental |
denotes |
essential agreement |
| p1_all8 |
3145-3148 |
Intervention |
denotes |
NAL |
| p2_i5 |
3145-3148 |
Pharmacological |
denotes |
NAL |
| p1_all9 |
4035-4043 |
Intervention |
denotes |
amikacin |
| p2_i6 |
4035-4043 |
Pharmacological |
denotes |
amikacin |
| p1_all10 |
4302-4316 |
Intervention |
denotes |
amikacin (AMK) |
| p1_all11 |
4384-4526 |
Population |
denotes |
131 consecutive non duplicated P. aeruginosa strains isolated during February 2004-January 2005, resistant to AMK according to the W/A system. |
| p1_all12 |
4527-4568 |
Outcome |
denotes |
Identification and susceptibility testing |
| p2_i7 |
4688-4703 |
Pharmacological |
denotes |
aminoglycosides |
| p2_i8 |
4740-4756 |
Pharmacological |
denotes |
gentamicin (GEN) |
| p2_i9 |
4767-4783 |
Pharmacological |
denotes |
tobramycin (TOB) |
| p1_all13 |
4767-4784 |
Intervention |
denotes |
tobramycin (TOB): |
| p1_all14 |
5618-5716 |
Outcome |
denotes |
Percentages of agreement in clinical categories between W/A and microdilution for GEN, TOB and AMK |
| p2_o25 |
5705-5716 |
Physical |
denotes |
TOB and AMK |
| p2_o30 |
6357-6403 |
Physical |
denotes |
susceptibility testing of P. aeruginosa to AMK |
| p1_all15 |
6739-6765 |
Intervention |
denotes |
AST-N020 or AST-N041 cards |
| p1_all16 |
7035-7043 |
Intervention |
denotes |
AST-N041 |
| p1_all17 |
7167-7361 |
Intervention |
denotes |
20 Kpn producing TEM, SHV or CTX-M ESBL, 39 Eco hyperproducing chromosomal AmpC (HAmpC), 11 Kpn ESBL(+) and lacking porins [POR (-)] and 22 Kpn with plasmid-mediated AmpC beta-lactamase (pACBL). |
| p2_i10 |
7189-7206 |
Physical |
denotes |
SHV or CTX-M ESBL |
| p2_i11 |
7585-7606 |
Pharmacological |
denotes |
amoxicillin-CLV (AMC) |
| p1_all18 |
7585-7710 |
Intervention |
denotes |
amoxicillin-CLV (AMC), piperacillin-tazobactam (PTZ), cefoxitin (FOX), cefotaxime (CTX), ceftazidime (CAZ) and cefepime (FEP) |
| p2_i12 |
7608-7637 |
Pharmacological |
denotes |
piperacillin-tazobactam (PTZ) |
| p2_i13 |
7639-7654 |
Pharmacological |
denotes |
cefoxitin (FOX) |
| p2_o37 |
7639-7710 |
Physical |
denotes |
cefoxitin (FOX), cefotaxime (CTX), ceftazidime (CAZ) and cefepime (FEP) |
| p2_i14 |
7656-7672 |
Pharmacological |
denotes |
cefotaxime (CTX) |
| p2_i15 |
7674-7691 |
Pharmacological |
denotes |
ceftazidime (CAZ) |
| p1_all19 |
7985-8010 |
Outcome |
denotes |
MICs of AMC, PTZ, and FOX |
| p1_all20 |
8081-8108 |
Outcome |
denotes |
CTX, CAZ, and FEP with N020 |
| p1_all21 |
8850-8874 |
Outcome |
denotes |
MICs of CTX, CAZ and FEP |
| p2_i16 |
8889-8897 |
Pharmacological |
denotes |
AST-N020 |
| p1_all22 |
8889-8910 |
Intervention |
denotes |
AST-N020 and AST-N041 |
| p1_all23 |
9334-9359 |
Population |
denotes |
humans on rare occasions. |
| p1_all24 |
9529-9548 |
Intervention |
denotes |
disk diffusion (DD) |
| p1_all25 |
9755-10259 |
Intervention |
denotes |
Sixty-one isolates representing 15 genera and 25 different species including Buttiauxella, Cedecea, Ewingella, Kluyvera, Leminorella, Rahnella, and Yokenella from the strain collection of the Centers for Disease Control and Prevention were tested by the DD and BMD reference methods using Mueller-Hinton (MH) agar and cation-adjusted MH broth at 35C for 18-20 h. Antimicrobial agents included aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillins, and trimethoprim-sulfamethoxazole. |
| p2_i17 |
10148-10210 |
Pharmacological |
denotes |
aminoglycosides, carbapenems, cephalosporins, fluoroquinolones |
| p2_i18 |
10229-10258 |
Pharmacological |
denotes |
trimethoprim-sulfamethoxazole |
| p1_all26 |
10323-10372 |
Outcome |
denotes |
Identification and susceptibility of the isolates |
| p2_o51 |
10323-10372 |
Other |
denotes |
Identification and susceptibility of the isolates |
| p1_all27 |
10597-10599 |
Outcome |
denotes |
CA |
| p1_all28 |
10614-10624 |
Intervention |
denotes |
ampicillin |
| p2_i19 |
10614-10624 |
Pharmacological |
denotes |
ampicillin |
| p1_all29 |
10637-10646 |
Intervention |
denotes |
cefazolin |
| p2_i20 |
10637-10646 |
Pharmacological |
denotes |
cefazolin |
| p1_all30 |
10699-10708 |
Intervention |
denotes |
cefazolin |
| p2_i21 |
10699-10708 |
Pharmacological |
denotes |
cefazolin |
| p2_o57 |
11161-11164 |
Physical |
denotes |
BMD |
| p2_o62 |
11775-11851 |
Other |
denotes |
Smet, C. Nonhoff, S. Crevecoeur, R. De Mendonça, M. Struelens (Brussels, BE) |
| p2_i22 |
12087-12097 |
Pharmacological |
denotes |
cefotaxime |
| p1_all31 |
12087-12151 |
Intervention |
denotes |
cefotaxime, cefepime and ceftazidime alone and with clavulanate. |
| p2_i23 |
12112-12150 |
Pharmacological |
denotes |
ceftazidime alone and with clavulanate |
| p1_all32 |
12352-12495 |
Population |
denotes |
Methods: A total of 100 E. coli strains (83 ESBL and 16 AmpC producing E. coli) and 26 Klebsiella spp isolates (26 ESBL strains) were included. |
| p2_o66 |
12500-12516 |
Physical |
denotes |
presence of ESBL |
| p1_all33 |
12512-12516 |
Intervention |
denotes |
ESBL |
| p1_all34 |
12649-12653 |
Outcome |
denotes |
ESBL |
| p2_o67 |
12649-12653 |
Physical |
denotes |
ESBL |
| p1_all35 |
13167-13194 |
Outcome |
denotes |
mean time to obtain results |
| p2_o72 |
13167-13194 |
Other |
denotes |
mean time to obtain results |
| p1_all36 |
13246-13262 |
Outcome |
denotes |
enzyme detection |
| p1_all37 |
13335-13362 |
Outcome |
denotes |
Sensitivity and specificity |
| p2_o75 |
13335-13362 |
Other |
denotes |
Sensitivity and specificity |
| p2_i24 |
14230-14240 |
Pharmacological |
denotes |
cefotaxime |
| p1_all38 |
14230-14294 |
Intervention |
denotes |
cefotaxime, cefepime and ceftazidime alone and with clavulanate. |
| p2_i25 |
14255-14293 |
Pharmacological |
denotes |
ceftazidime alone and with clavulanate |
| p1_all39 |
14878-14896 |
Outcome |
denotes |
Production of ESBL |
| p2_o84 |
14878-14896 |
Physical |
denotes |
Production of ESBL |
| p2_i26 |
14945-14982 |
Pharmacological |
denotes |
ceftazidime, cefotaxime and cefepime) |
| p1_all40 |
14945-15062 |
Intervention |
denotes |
ceftazidime, cefotaxime and cefepime), combined disc method (Oxoid) and PCR for bla TEM, bla SHV and bla CTX-M genes. |
| p2_i27 |
15110-15116 |
Pharmacological |
denotes |
CTX-M9 |
| p1_all41 |
15154-15165 |
Outcome |
denotes |
TEM enzymes |
| p1_all42 |
15477-15502 |
Outcome |
denotes |
table.Overall sensitivity |
| p1_all43 |
15634-15661 |
Outcome |
denotes |
mean time to obtain results |
| p2_o89 |
15634-15661 |
Other |
denotes |
mean time to obtain results |
| p1_all44 |
16227-16281 |
Intervention |
denotes |
indicator antibiotics with and without clavulanic acid |
| p2_i28 |
16237-16281 |
Pharmacological |
denotes |
antibiotics with and without clavulanic acid |
| p1_all45 |
16446-16522 |
Population |
denotes |
Strains originated mainly from urine (n = 104) and blood specimens (n = 18). |
| p2_o95 |
16497-16512 |
Physical |
denotes |
blood specimens |
| p1_all46 |
16654-16716 |
Intervention |
denotes |
double disc test method and by ESBL combination discs (Oxoid). |
| p1_all47 |
16867-16951 |
Intervention |
denotes |
cefepime, ceftazidime, and cefotaxime alone and in combination with clavulanic acid. |
| p2_i29 |
16877-16888 |
Pharmacological |
denotes |
ceftazidime |
| p2_i30 |
16894-16950 |
Pharmacological |
denotes |
cefotaxime alone and in combination with clavulanic acid |
| p1_all48 |
17232-17264 |
Intervention |
denotes |
TEM + chromosomal beta-lactamase |
| p1_all49 |
17558-17574 |
Outcome |
denotes |
TEM-like enzymes |
